Market Overview

MiMedx Receives Additional Nasdaq Listing Notice Due to Late Form 10-Q


MiMedx Receives Additional Nasdaq Listing Notice Due to Late Form 10-Q

PR Newswire

MARIETTA, Ga., Aug. 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ:MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received written notification, as expected, from the Nasdaq Stock Market indicating that the Company's failure to timely file a Form 10-Q for the period ended June 30, 2018 could serve as an additional basis for delisting, and that the Company should be prepared to address the additional delinquency at its already scheduled hearing in September before a Nasdaq Hearings Panel (the "Panel"). Nasdaq previously notified the Company that it was not in compliance with Nasdaq Listing Rule 5250(c) due to the delay in the Company's filing of the Form 10-K for the year ended December 31, 2017 and Form 10-Q for the period ended March 31, 2018.

The Nasdaq notice has no immediate effect on the listing of the Company's common stock. As announced earlier this week, the Panel granted the Company's request for a listing extension, which allows for the continued trading of the Company's common stock on the Nasdaq Stock Market until the Panel makes its determination on the Company's appeal of the Nasdaq staff's delisting notification.  The Panel hearing will take place on September 13, 2018, and the Panel is expected to make its determination sometime after the hearing.

The Company expects to provide an update regarding its continued listing status once the Panel makes its determination sometime after the hearing.

About MiMedx    
MiMedx® is a leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind the Company's mission to provide physicians products and tissues to help the body heal itself. The Company processes the human placental tissue utilizing its proprietary PURION® Process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.3 million allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit

Safe Harbor Statement
This press release includes forward-looking statements including statements regarding expected future compliance with SEC reporting and Nasdaq listing requirements, and continued Nasdaq listing. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements.

Actual results may differ materially from those set forth in the forward-looking statements. There can be no assurance that the Panel will grant the Company's request for continued listing on Nasdaq, or that the Company's plans to exercise diligent efforts to maintain the listing of its common stock on Nasdaq will be successful. For more detailed information on the risks and uncertainties, please review the Risk Factors section of the Company's most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.

Cision View original content:

SOURCE MiMedx Group, Inc.

View Comments and Join the Discussion!